通过向的TGF-β激动剂选择性免疫沉默
bioRxiv : the preprint server for biology
|February 9, 2026
概括
向的TGF-β激动剂选择性地使病原性T和B细胞沉默,为自身免疫和炎症性疾病提供了有前途的新疗法,并提高了安全性和有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 药物发现 药物发现 药物发现
背景情况:
- 目前用于免疫疾病的疗法耗尽T细胞和B细胞,但具有包括不良事件和复发在内的局限性.
- 转化生长因子β (TGF-β) 具有免疫抑制性质,可以用于治疗益处.
研究的目的:
- 开发一种新的治疗策略,使用向的TGF-β激动剂来选择性地沉默致病性T细胞和B细胞.
- 在临床前模型中评估细胞选择性TGF-β激素的疗效和安全性.
主要方法:
- 开发虫衍生TGF-β模仿激素剂,针对特定的T细胞 (CD4,CD8) 和B细胞 (CD19) 种群.
- 在小鼠和人类脏器官中评估T细胞激活和扩张.
- 评估人类脏器官中的抗体反应和B细胞分化.
- 在免疫性疾病的小鼠模型中测试细胞类型特定的TGF-β激动剂.
主要成果:
- 针对T细胞的TGF-βagonists有效地抑制了抗原刺激的T细胞激活和扩张.
- 针对CD4 T细胞的激动剂将T细胞重新编程为静止或调节性表型,沉默抗体反应.
- CD19 B 细胞向激素破坏了 B 细胞分化到抗体分泌细胞的过程.
- 细胞选择性TGF-β激动剂在小鼠模型中改善了疾病活性,具有最小的脱效应.
结论:
- 细胞选择性TGF-β激动体是一种多功能治疗策略,用于精确的免疫功能沉默.
- 这种方法为治疗免疫性疾病提供了广泛免疫细胞枯竭的有希望的替代方案.
相关概念视频
TGF - β Signaling Pathway
10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.7K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.7K
What is the Immune System?
131.2K
Overview
131.2K
Humoral Immune Responses
84.1K
Overview
84.1K
Adrenergic Agonists: Therapeutic Uses
2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Glucagon-like Receptor Agonists
995
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
995


